RTX-134 / Rubius Therap - LARVOL DELTA

Safety and Tolerability of RTX-134 in Adults With Phenylketonuria (clinicaltrials.gov) - P1b | N=1 | Terminated | Sponsor: Rubius Therapeutics | N=12 ➔ 1 | Trial completion date: Mar 2035 ➔ Dec 2022 | Active, not recruiting ➔ Terminated | Trial primary completion date: Mar 2035 ➔ Dec 2022; The trial was discontinued by the Sponsor

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Metabolic Disorders • Phenylketonuria • Rare Diseases

Safety and Tolerability of RTX-134 in Adults With Phenylketonuria (clinicaltrials.gov) - P1b; N=12; Active, not recruiting; Sponsor: Rubius Therapeutics; Trial completion date: May 2020 ➔ Mar 2035; Trial primary completion date: Apr 2020 ➔ Mar 2035

Clinical • Trial completion date • Trial primary completion date • Metabolic Disorders • Phenylketonuria • Rare Diseases

Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies. (PubMed, BioDrugs) - "With a number of agents in clinical trials (e.g., dexamethasone 21-phosphate in ataxia telangiectasia, asparaginase in pancreatic cancer/acute lymphoblastic leukemia, thymidine phosphorylase in mitochondrial neurogastrointestinal encephalomyopathy, RTX-134 in phenylketonuria, etc.), this leading article summarizes the ongoing efforts in developing these agents, focuses on the clinical progress, and provides a brief background into engineered RBCs and the different ways in which they can be exploited for therapeutic/diagnostic purposes. References to available data on safety, efficacy, and tolerability are reported. Due to the continuous progress in this field, the information is updated as of January 2020 from databases, websites, and press releases of the involved companies and information that is in the public domain."

Clinical • Journal

Safety and Tolerability of RTX-134 in Adults With Phenylketonuria (clinicaltrials.gov) - P1b; N=12; Active, not recruiting; Sponsor: Rubius Therapeutics; Recruiting ➔ Active, not recruiting; Initiation date: Sep 2019 ➔ Jan 2020

Clinical • Enrollment closed • Trial initiation date

Rubius Therapeutics Highlights Preclinical Oncology Data at Society for Immunotherapy of Cancer Annual Meeting and AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire, Rubius Therapeutics) - “As preclinical proof of concept, mouse red cells were chemically engineered with hundreds of thousands of copies of the major histocompatibility complex (MHC) I loaded with the gp100 peptide, a melanoma antigen, 4-1BBL and IL-12 on the cell surface and were tested in a B16-F10 melanoma mouse model. These cells (mRBC-gp100-4-1BBL-IL-12 ) nearly eliminated lung metastases at the highest dose levels. mRBC-gp100-4-1BBL-IL-12 promoted gp100-specific T cell expansion in the circulation, secondary lymphoid organs and lungs.”

Preclinical • Tumor-specific neoantigens

Rubius Therapeutics Announces Poster Presentations at the 2019 American Association for Cancer Research Annual Meeting (GlobeNewswire, Rubius Therapeutics) - "Rubius Therapeutics...today announced that the company will present preclinical data from its oncology pipeline of Red Cell Therapeutics™ at the 2019 American Association for Cancer Research (AACR) Annual Meeting...Rubius Therapeutics will be presenting preclinical data from our growing oncology pipeline that support two potentially groundbreaking allogeneic, off-the-shelf, cellular immuno-oncology approaches, enabled by our RED PLATFORM..."

Preclinical